Ulcerative Colitis is a chronic autoimmune disorder of the colon characterized by alternating periods of remission and relapse. Disease flares occur in a random way and are currently unpredictable.

Our novel prognostic biomarker can identify patients with a high risk of relapsing, enabling clinicians to escalate treatment before the onset of symptoms and keep patients in remission (figure below). The test is based on mucosal samples from the colon, which might sounds challenging at first. However, endoscopy represent that mainstay evaluating the disease activity, meaning the test can be incorporated without need for additional endoscopies.